Patents by Inventor Roger MacKenzie
Roger MacKenzie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240076389Abstract: AXL-specific antibodies and uses therefor are described, including monoclonal and single domain antibodies. Such antibodies bind to cell surface expressed human AXL at an epitope in an immunoglobulin-like (IgL) domain of the AXL ectodomain. The antibody may be used in an antibody-drug conjugate (ADC), for example in the treatment, detection or staging of cancer. The antibody may be biparatopic.Type: ApplicationFiled: June 27, 2023Publication date: March 7, 2024Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Kevin HENRY, Maria Luz JARAMILLO, Colin Roger MACKENZIE, Anne MARCIL
-
Patent number: 11739154Abstract: AXL-specific antibodies and uses therefor are described, including monoclonal and single domain antibodies. Such antibodies bind to cell surface expressed human AXL at an epitope in an immunoglobulin-like (IgL) domain of the AXL ectodomain. The antibody may be used in an antibody-drug conjugate (ADC), for example in the treatment, detection or staging of cancer. The antibody may be biparatopic.Type: GrantFiled: September 10, 2018Date of Patent: August 29, 2023Assignee: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Kevin Henry, Maria Luz Jaramillo, Colin Roger Mackenzie, Anne Marcil
-
Publication number: 20200277386Abstract: AXL-specific antibodies and uses therefor are described, including monoclonal and single domain antibodies. Such antibodies bind to cell surface expressed human AXL at an epitope in an immunoglobulin-like (IgL) domain of the AXL ectodomain. The antibody may be used in an antibody-drug conjugate (ADC), for example in the treatment, detection or staging of cancer. The antibody may be biparatopic.Type: ApplicationFiled: September 10, 2018Publication date: September 3, 2020Inventors: Kevin HENRY, Maria Luz JARAMILLO, Colin Roger MACKENZIE, Anne MARCIL
-
Patent number: 10259864Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.Type: GrantFiled: December 20, 2017Date of Patent: April 16, 2019Assignee: National Research Council of CanadaInventors: Mehdi Arbabi Ghahroudi, Ali Riazi, Christine M. Szymanski, Greg Hussack, Jamshid Tanha, Roger MacKenzie
-
Publication number: 20180142000Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.Type: ApplicationFiled: December 20, 2017Publication date: May 24, 2018Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Mehdi ARBABI GHAHROUDI, Ali RIAZI, Christine M. SZYMANSKI, Greg HUSSACK, Jamshid TANHA, Roger MACKENZIE
-
Publication number: 20180134769Abstract: The present invention is directed to Clostridium difficile toxin-specific antibodies, compositions, and uses thereof. The anti-toxin antibodies may be specific for either TcdA or TcdB. The invention also includes methods of treating a Clostridium difficile infection, methods of capturing Clostridium difficile toxins, and methods of detecting Clostridium difficile toxins.Type: ApplicationFiled: September 22, 2017Publication date: May 17, 2018Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Greg HUSSACK, Mehdi ARBABI-GHAHROUDI, Roger MACKENZIE, Jamshid TANHA
-
Patent number: 9926363Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.Type: GrantFiled: October 24, 2013Date of Patent: March 27, 2018Assignee: National Research Council of CanadaInventors: Mehdi Arbabi Ghahroudi, Ali Riazi, Christine M. Szymanski, Greg Hussack, Jamshid Tanha, Roger MacKenzie
-
Patent number: 9771416Abstract: The present invention is directed to Clostridium difficile toxin-specific antibodies, compositions, and uses thereof. The anti-toxin antibodies may be specific for either TcdA or TcdB. The invention also includes methods of treating a Clostridium difficile infection, methods of capturing Clostridium difficile toxins, and methods of detecting Clostridium difficile toxins.Type: GrantFiled: October 25, 2011Date of Patent: September 26, 2017Assignee: National Research Council of CanadaInventors: Greg Hussack, Mehdi Nath Arbabi-Ghahroudi, Roger Mackenzie, Jamshid Tanha
-
Patent number: 9327022Abstract: The invention relates to antibodies specific to serum albumins. More specifically, the invention relates to camelid single domain antibodies and pentabodies binding to serum albumins of various species with various affinities.Type: GrantFiled: October 14, 2009Date of Patent: May 3, 2016Assignee: National Research Council of CanadaInventors: Jianbing Zhang, Wangxue Chen, C. Roger MacKenzie, Mehdi Arbabi, Shenghua Li
-
Publication number: 20150307597Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.Type: ApplicationFiled: October 24, 2013Publication date: October 29, 2015Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Mehdi ARBABI GHAHROUDI, Ali RIAZI, Christine M. SZYMANSKI, Greg HUSSACK, Jamshid TANHA, Roger MACKENZIE
-
Publication number: 20130230537Abstract: The present invention is directed to Clostridium difficile toxin-specific antibodies, compositions, and uses thereof. The anti-toxin antibodies may be specific for either TcdA or TcdB. The invention also includes methods of treating a Clostridium difficile infection, methods of capturing Clostridium difficile toxins, and methods of detecting Clostridium difficile toxins.Type: ApplicationFiled: October 25, 2011Publication date: September 5, 2013Inventors: Greg Hussack, Mehdi Nath Arbabi-Ghahroudi, Roger Mackenzie, Jamshid Tanha
-
Publication number: 20110282036Abstract: The invention relates to antibodies specific to serum albumins. More specifically, the invention relates to camelid single domain antibodies and pentabodies binding to serum albumins of various species with various affinities.Type: ApplicationFiled: October 14, 2009Publication date: November 17, 2011Inventors: Jianbing Zhang, Wangxue Chen, C. Roger Mackenzie, Mehdi Arbabi, Shenghua Li
-
Patent number: 7872105Abstract: A novel single domain antibody AFAI and fragments thereof which has specific affinity for binding to carcinoma, and especially lung carcinoma. This antibody, and portions thereof, can be used, inter alia in the diagnosis and treatment of carcinoma.Type: GrantFiled: May 25, 2006Date of Patent: January 18, 2011Assignees: National Research Council of Canada, Ottawa Hospital Research InstituteInventors: Colin Roger Mackenzie, Jianbing Zhang, Thanh-Dung Nguyen, Qinggang Li, Kien Trung Mai
-
Patent number: 7655412Abstract: There is provided a method of forming a multimeric complex having affinity for a target. The method comprises: obtaining a plurality of self-assembly molecules, said self-assembly molecules including complementary self-assembly units such as verotoxin subunit B, each of which is operatively connected to an interaction domain such as a single domain antibody specific for the target; and combining said self-assembly molecules such that at least three said self-assembly units simultaneously bind to one another so as to permit the single domain antibodies to bind the target.Type: GrantFiled: November 29, 2002Date of Patent: February 2, 2010Assignee: National Research Council of CanadaInventors: C. Roger Mackenzie, Jianbing Zhang
-
Publication number: 20090226942Abstract: Disclosed herein are lung cancer specific binding agents, as well as related amino acid and nucleic acid sequences. Methods of using such agents in the diagnosis and treatment of treat lung cancer are also disclosed. In an embodiment of the invention there is provided an antibody or fragment thereof comprising the sequence Ser Gly Asn Gly Gly Thr in the region corresponding to the CDR 2.Type: ApplicationFiled: March 27, 2008Publication date: September 10, 2009Inventors: Colin Roger MacKenzie, Qinggang Li, Jianbing Zhang
-
Publication number: 20060159687Abstract: Disclosed herein are peptides that include aerolysin (or an aerolysin homolog) linked to an agent that specifically binds to a lung cancer cell, as well as nucleic acid sequences that encode such peptides. Methods of using such peptides and nucleic acid sequences to treat lung cancer are also disclosed.Type: ApplicationFiled: March 2, 2004Publication date: July 20, 2006Inventors: J. Buckley, Roger MacKenzie